The new outstation is located on the Bayer HealthCare campus, within the CoLaborator building that is rented out by Bayer to smaller companies and start-ups. NMI TT Pharmaservices will be using the new and already functional laboratory space to provide life science researchers with its proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses as well as biomarker identification projects for industrial clients and academic partners alike. In addition, the new office will play a key role for advancing NMI TT Pharmaservices’ market positioning by expanding its business activities beyond the existing well-established customer base.

“We are very excited to start this new phase in our company’s development,” commented Prof. Dr. Hugo Hämmerle, CEO of NMI TT GmbH. “We see our expansion to Berlin as a unique opportunity to intensify our business development efforts across the international pharma and biotech market. This move also happens at a particularly promising time in the development of the proteomics field, which we are keen to help drive forward in the years to come, now through both our Reutlingen team and our new Berlin unit.

“The chances of this new endeavour are manifold,” added Dr. Christoph Sachse, Site Head of the NMI TT Berlin operation. “We expect that being closer to the needs of pharma R&D scientists and the lively Berlin biotech community will substantially help us in further developing and in marketing our wide range of contract research offerings, in particular our multiplex protein profiling platform, but also our capabilities in cellular assays and in generating customised cell lines.”

As a part of the inauguration, a symposium entitled “Protein Biomarkers: Technologies and Applications”, jointly organised by NMI TT Pharmaservices and Bayer HealthCare, is being held today at the CoLaborator in Berlin. The symposium will serve as a forum to foster mutually beneficial scientific discussions between scientists of the two organisations, together with international experts in the field and numerous guests from Berlin’s research community.

About NMI TT Pharmaservices

NMI TT Pharmaservices is a preclinical Contract Research Organisation dedicated to provide integrated experts services to customers in pharma, biotech, medtech, and academia. The company’s business is focused on high-quality services and R&D support for drug discovery and development, with a strong track record and a broad portfolio of offerings in the areas of biochemistry, protein profiling, molecular biology, and safety pharmacology. NMI TT GmbH, founded in 2002, is a spin-out of the Natural and Medical Sciences Institute (NMI) at the University of Tübingen, with its headquarters in Reutlingen and, since 2015, with a new branch in Berlin, Germany.

Speakers at the CoLaborator Biomarker Symposium included Dr. Markus Templin (NMI), Prof. Dr. Hanno Langen (Roche), Dr. Thomas Joos (NMI), Prof. Dr. Siegfried Neumann (TU Darmstadt), Dr. Gerrit Erdmann (NMI TT), Dr. Christoph Sachse (NMI TT), Dr. Manrico Paulitschke (Provitro), Dr. Jörg Knäblein (Bayer), Dr. Julia Gross (University of Göttingen), Dr. Hans-Dieter Pohlenz (Berlin), Dr. Michael Drosch (Calico), Prof. Dr. Hugo Hämmerle (NMI/NMI TT), Dr. Arndt Schmitz (Bayer), Dr. Thomas Krahn (Bayer).